From the clinical researcher’s desk

Introduction-

Mulmina® Mango, a health drink, is rich in antioxidants, vitamins, minerals and mesonutrients. It contains extracts from mango, Centella asiatica and turmeric which are important mesonutrients. 

A study evaluated the efficacy and safety of Mulmina® Mango as an adjunct therapy in mild-to-moderate COVID-19 positive patients who were quarantined or hospitalized in a dedicated COVID health centre.

Study design and method-

• Study arms:

» Treatment arm A: Standard of care treatment and Mulmina® Mango

» Treatment arm B: Standard of care treatment

• Assessment was performed on a daily basis till discharge based on Questionnaires for faster recovery (ordinal scale and clinical symptom scale).
• Depression Anxiety Stress Scales (DASS), Hamilton and WHO 5, Health-related quality of life (HRQOL) were assessed on day 1 (baseline), day 3, day 7 and discharge.
• HRQOL questionnaire was assessed on day 1 (baseline), discharge and for 14 days telephonic follow-up.
• Real-time reverse transcription-polymerase chain reaction (RT-PCR) assay was performed on day 5.

Observations from the study-

Recovery rate

• Negative RT-PCR was reported in a significantly greater number of patients receiving treatment A comparing with treatment arm B.
• On day 6:

» 29.2% patients turned negative in Treatment arm A

» 16% patients turned negative in Treatment arm B

• Reduction of 2 points on ordinary recovery scale:

» In 41.7% patients of Treatment arm A

» In 16.7% patients of Treatment arm B

Dopamine levels

• A macroscale increase was reported in the average dopamine on the day of discharge in treatment arm A than in treatment arm B (239 vs. 89).

COVID-19 antibodies

On the day of discharge, immunoglobulin G (IgG) antibodies were significantly higher in Treatment arm A as compared with Treatment arm B (12.8 vs. -106.6).

Immune-boosting property

CD4 (cluster of differentiation 4) count: The average CD4 count significantly increased in treatment arm A while decreased in treatment arm B (129.8 vs. -75.7).

• CD8: The average CD8 count significantly increased in treatment arm A while decreased in treatment arm B (142.4 vs. -15.1)

Anti-inflammatory effect

CRP: A significant decrease in inflammatory marker CRP was noted in treatment arm A than the treatment arm B on the day of discharge (-13 vs. 1.2)

Anti-allergy (IgE)

An average increase in IgE was reported in both the treatment arms from visit 1 to discharge. Treatment arm A showed a greater IgE value than treatment arm B (median: 638.0 vs. 96.5).

Antioxidant property

Mulmina® mango contains an ORAC Value of 5668 per 200 mL pack.

Thus was concluded that-

• Intake of Mulmina® Mango along with standard treatment can help faster recovery and improve quality of life in COVID-19 patients.
• Mulmina® Mango administration can increase the CD4+T and CD8+T cells which play a vital role in maintaining immune function and viral clearance in the body.
• Additionally, Mulmina® Mango can also decrease CRP level which is correlated to disease resolution.